行情

RTRX

RTRX

Retrophin
NASDAQ

实时行情|Nasdaq Last Sale

19.11
-0.23
-1.19%
盘后: 19.11 0 0.00% 16:00 08/06 EDT
开盘
19.31
昨收
19.34
最高
19.82
最低
18.95
成交量
28.54万
成交额
--
52周最高
21.92
52周最低
8.98
市值
9.73亿
市盈率(TTM)
-7.4924
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测RTRX价格均价为29.14,最高价位38.00,最低价为21.00。

EPS

RTRX 新闻

更多
Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following upcoming virtual investor conferences in August: William Blair Biotech Focus Conference 2020 Date: Thursday,
GlobeNewswire · 3天前
Retrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates
Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 22:40
Retrophin Q2 EPS $(0.22) Beats $(0.55) Estimate, Sales $48.40M Beat $47.08M Estimate
Retrophin (NASDAQ:RTRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.55) by 60 percent. This is a 62.07 percent increase over losses of $(0.58) per share from the same
Benzinga · 07/30 20:13
Retrophin Reports Second Quarter 2020 Financial Results
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased eight percent to $48 million in the second quarter Cash & equi
GlobeNewswire · 07/30 20:01
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Retrophin EPS beats by $0.14, beats on revenue
Seeking Alpha · 07/30 04:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
Retrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/23 16:33

所属板块

生物技术和医学研究
-0.96%
制药与医学研究
-0.46%

热门股票

代码
价格
涨跌幅

RTRX 简况

Retrophin, Inc.是一家生物制药公司,专注于开发、收购和销售用于治疗严重、灾难或罕见疾病的疗法。它销售三种产品,包括Chenodal(鹅去氧胆酸)、Cholbam(胆酸)和Thiola(硫普罗宁)。其Chenodal在美国被批准用于治疗手术中由于疾病或高龄而造成不可接受健康风险的胆结石患者。Chenodal也一直用于脑腱黄瘤病(CTX)患者。其Cholbam在美国被批准用于治疗由于单一酶缺陷引起的胆汁酸合成障碍,并且进一步用于治疗过氧化小体疾病患者。它的Thiola在美国被批准用于预防严重纯合性胱氨酸尿症患者的胱氨酸(肾)结石。其候选产品包括Sparsentan、RE-024、RE-034和NGLY1。
展开

微牛提供Retrophin Inc(NASDAQ-RTRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的RTRX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易RTRX股票基本功能。